China lays out new vision for pharma distribution as it seeks benefits of scale
This article was originally published in Scrip
China is planning to promote the reform of the domestic pharmaceutical distribution industry under a new five-year plan for the 2011-15 period announced earlier this month by the ministry of commerce (MoC), in which a big increase in the number of retail pharmacies is also envisaged.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.